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C3 glomerulonephritis (C3GN) is a recently described
disorder that typically results from abnormalities in the
alternative pathway (AP) of complement. Here, we
describe the clinical features, kidney biopsy findings, AP
abnormalities, glomerular proteomic profile, and follow-up
in 12 cases of C3GN. This disorder equally affected all ages,
both genders, and typically presented with hematuria and
proteinuria. In both the short and long term, renal function
remained stable in the majority of patients with native
kidney disease. In two patients, C3GN recurred within
1 year of transplantation and resulted in a decline in
allograft function. Kidney biopsy mainly showed a
membranoproliferative pattern, although both mesangial
proliferative and diffuse endocapillary proliferative
glomerulonephritis were noted. AP abnormalities were
heterogeneous, both acquired and genetic. The most
common acquired abnormality was the presence of C3
nephritic factors, while the most common genetic finding
was the presence of H402 and V62 alleles of Factor H. In
addition to these risk factors, other abnormalities included
Factor H autoantibodies and mutations in CFH, CFI, and CFHR
genes. Laser dissection and mass spectrometry of glomeruli
from patients with C3GN showed accumulation of AP and
terminal complement complex proteins. Thus, C3GN results
from diverse abnormalities of the alternative complement
pathway leading to subsequent glomerular injury.
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C3 glomerulonephritis (C3GN) is a recently described entity
that shows a glomerulonephritis on light microscopy (LM);
bright C3 staining and the absence of C1q, C4, and
immunoglobulins (Ig) on immunofluorescence (IF) micro-
scopy; and mesangial and/or subendothelial electron-dense
deposits on electron microscopy (EM).1–3 Occasional intra-
membranous and subepithelial deposits are also frequently
present.3 The term ‘C3 glomerulopathy’ is often used to
include C3GN and dense deposit disease (DDD), both of
which result from dysregulation of the alternative pathway
(AP) of complement.1,3–5 C3GN and DDD may be difficult to
distinguish from each other on LM and IF studies. However,
EM shows mesangial and/or subendothelial, intramembra-
nous, and subepithelial deposits in C3GN, while dense
osmiophilic deposits are present along the glomerular
basement membranes and in the mesangium in DDD. Both
C3GN and DDD are distinguished from immune complex-
mediated glomerulonephritis by the lack of Ig staining on IF.6
Very few papers have described the clinical and patholo-
gical findings in C3GN.2,3 The aim of this study was to
present a comprehensive description of the clinical features,
renal biopsy findings, complement abnormalities, treatment,
and follow-up in C3GN. We describe in detail 12 patients
with C3GN, 2 of whom developed recurrent disease following
allograft transplantation. We also performed laser dissection
and mass spectrometry in eight cases to define the glomerular
proteomic profile of this disease.
RESULTS
Clinical features
Our study included 12 patients with C3GN (Table 1). All
patients except one (case 12) were treated at the Mayo Clinic.
Ten patients maintained native kidney function, and in two
patients, the disease was recurrent in allografts. Sex distribu-
tion was equal (six females and six males) and age
ranged from 8 to 73 years (mean, 42.5 years). The serum
creatinine at presentation ranged from 0.6 to 3.1mg/dl
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(mean, 1.5mg/dl) with a glomerular filtration rate of 31 to
161ml/min (mean, 63.4ml/min).
Of the 10 patients with native kidney function, 9 were
hypertensive. All had hematuria and proteinuria (six patients
had 420 red blood cells/high power field and 425%
dysmorphic red blood cells). Twenty-four-hour urinary
protein ranged from 615 to 15,000mg/24 h (mean,
5762mg/24 h). C3 levels were low in nine patients, varying
from 12 to 76mg/dl (mean, 40.4mg/dl; normal range
75–175mg/dl). C4 levels were borderline low in only one
patient (13mg/dl; normal range 14–40mg/dl). Evaluation for
hepatitis B and C, antinuclear antigen, double-stranded
DNA, and cryoglobulins were uniformly negative. Two
patients showed a small monoclonal gammopathy spike—
one patient had IgG kappa and the other had IgM kappa on
serum immunofixation studies. Bone marrow studies in these
two patients showed o10% plasma cells. Two patients also
had strong family history of renal disease. None of patients
had ocular drusen.
Of the two patients with recurrent C3GN (patients 11 and
12), one was a 31-year-old male patient and the other patient
was a 21-year-old female patient. Recurrence of C3GN was
noted in both of these patients within 1–1.5 years of renal
allograft transplantation, and was heralded by a rise in serum
creatinine, the development of non-nephrotic range protei-
nuria, and low serum C3 levels.
Kidney biopsy findings
In the 10 patients with native kidney function, biopsies
uniformly showed a proliferative glomerulonephritis on LM.
In eight cases, the pattern was membranoproliferative
glomerulonephritis (MPGN) with mesangial and endocapil-
lary proliferation with mononuclear cells, glomerular capil-
lary wall remodeling with double contour formation, and
lobular accentuation of the capillary tufts. In the remaining
two cases, the biopsy showed a diffuse endocapillary
proliferative glomerulonephritis with endocapillary prolif-
eration and influx of both mononuclear cells and neutro-
phils. One case showed small crescents, and one case showed
a focal area of fibrinoid necrosis. Tubular atrophy and
interstitial fibrosis ranged from 0 to 25% of the cortex, with a
mean of 15% (Table 2).
IF microscopy for C3 is the hallmark of C3GN. All cases
showed bright staining for C3 in the mesangium and
glomerular capillary walls. In two cases, C3 staining was also
present along the tubular basement membranes. No case
showed significant staining for IgG, IgM, C1q, kappa, and
lambda light chains. Trace staining for IgG and light chains
was present in two cases.
EM showed subendothelial and mesangial electron-dense
deposits in all cases. Eight cases also showed subepithelial
deposits and eight cases showed a few intramembranous deposits.
The deposits were amorphous and appeared lighter and less
sharply demarcated than immune-type electron-dense deposits.
The subepithelial deposits raised the possibility of post-
infectious glomerulonephritis (see Discussion). Double contour
formation was present in eight cases with subendothelial
expansion by cellular elements, electron-dense deposits, and
new basement membrane formation. Representative LM, IF,
and EM are shown in Figure 1.
Renal biopsy of the two transplant cases showed recurrent
C3GN. LM showed a MPGN, IF showed bright C3 staining
in the mesangium and capillary walls, and EM showed
mesangial and capillary wall deposits. In patient 12
(transplant case 2), subepithelial deposits and intramembra-
nous deposits were present. Recurrent C3GN first appeared
as a mesangial proliferative glomerulonephritis, and subse-
quently evolved and progressed to a MPGN. This course is in
keeping with the previously described biopsy findings in cases
of recurrent MPGN.7
Table 1 | Laboratory evaluation of C3GN patients
Patient Age/sex
Serum Cr at
presentation
(mg/dl) Urinalysis RBC/HPF
Urinary protein
(mg/24h) C3/C4mg/dl
Serum creatinine at
follow-up
1 71/F 1.7 41–50, o25% dRBC 614 46/24 0.78 (5 months)
2 52/F 1.44 50–100, 425% dRBC 6389 76/26 1.5 (3 months)
3 14/M 1.3 21–30, 425% dRBC 15760 19/13 1.3 (2.5 years)
4 60/M 1.1 50–100, 425% dRBC 874 57/35 1.4 (4 years)
5 47/F 3.1 21–30, no dRBC 204 while on
dialysis
56/47 On dialysis 4 months
after presentation
6 22/M 2.02 50–100 10390 12/normal 1.6 (4 months)
7 73/M 2.1 31–40, 425% dRBC 1700 39/33 1.7 (8 months)
8 8/F 0.5 NAa 631 42/14 0.7 (23 years)
9 36/M 1.1 3–10, 425% dRBC 9740 85/14 0.9 (2 years)
10 42/F 0.6 4–10, 425% dRBC 614 17/18 0.69 (4 years)
11 31/M 1.7 (baseline) 41–50, o25% dRBC 2360 (1.7 g 4
years later)
72/6 2.9 (66 months)
recurrence within 1 year
12 21/F 1.6 (baseline) 51–100, 425% dRBC 5730 40/27 2.1 (17 months)
recurrence within 1 year
Abbreviations: C3GN, C3 glomerulonephritis; dRBC, dysmorphic RBC; HPF, high power field; RBC, red blood cell.
Normal C3/C4 as per notes; C3 normal range (75–175mg/dl); C4 normal range (14–40mg/dl).
aUA at presentation at not available, latest at follow up 23 years later shows on 1–3RBC/HPF.
466 Kidney International (2012) 82, 465–473
or ig ina l a r t i c l e S Sethi et al.: C3 glomerulonephritis
Evaluation of the AP of complement
Functional and genetic studies of the AP identified
autoantibodies or mutations in complement genes in 8 of
12 patients. The remaining patients (patients 3, 4, 5, and 11)
carried CFH variants that are associated with an increase in
baseline AP activity (Table 3).
Five patients, including one patient with recurrent C3GN,
were positive for C3Nefs and one patient was positive for
a b c
d e f
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Figure 1 |Representative light, immunofluorescence, and electron microscopy (EM) in C3 glomerulonephritis (C3GN). (a–c) Light
microscopy showing different pattern of injury of the three different cases of C3GN. (a) shows a predominantly mesangial proliferative
glomerulonephritis (PAS 20 ), (b) shows a membranoproliferative glomerulonephritis (PAS 40 ), and (c) shows a diffuse endocapillary
proliferative glomerulonephritis with numerous infiltrating neutrophils within the glomerular capillaries (PAS 40 ). (d–f) Three different
cases of C3GN showing bright C3 in the mesangium and/or along capillary walls (40 ). (g–i) Three different cases of C3GN showing large
mesangial (black arrow), subendothelial deposits (thick black arrow), and subepithelial deposits (white arrow) on EM.
Table 2 | Kidney biopsy findings of C3GN patients
Patient
Pattern of injury, GS/
total glomeruli
Tubulointerstitial
scarring
Immunofluorescence
microscopy (CW and
mesangial) Electron microscopy
1 MPGN, 2/10 25 C3 (2+) SE, SU, MES
2 DPGN, 4/23 25 C3+, trace to 1+ lambda
and C1q
SE, SU, IN, MES
3 MPGN,2/29 10 C3 (3+) SE, IN, MES, TBM
4 MPGN, 0/18 10 C3 (3+) SE, SU, IN, MES,TBM
5 DPGN, 3/10 20 C3 (3+) SE, SU, MES
6 MPGN, with crescents, 2/9 5 C3 (3+) SE, SU, IN, MES
7 MPGN, 0/3 25 C3 (3+) SE, SU, IN, MES
8 MPGN, 0/12 0 C3 (intensity not
documented)
SE, IN, MES
9 MPGN, 1/23, with
secondary FSGS
20 C3 (3+) SE, SU, IN, MES
10 MPGN, 1/12 5 C3 (3+) SE, SU, IN, MES
11 (tx) MPGN 10 C3 (3+) SE, MES
12 (tx) MPGN, 3/23 25 C3 (3+) SE, SU, IN, MES
Abbreviations: C3GN, C3 glomerulonephritis; CW, capillary wall; DPGN, diffuse proliferative glomerulonephritis; GS, globally sclerosed; IN, intramembranous; MES, mesangial;
MPGN, membranoproliferative glomerulonephritis; SE, subendothelial; SU, subepithelial.
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Factor H autoantibodies (FHAAs). Mutations were found in
three patients and included a frameshift in CFH (c.2171delC,
p.Thr724fsSTOP725) (patient 1) that has not been described
in C3GN or DDD and missense variants in exon 6 of CFI
(c.782G4A, p.Gly261Asp) (patient 10) and CFHR5 (c.646-
647AA4TT, p.Asn216Phe)(patient 2). Risk alleles that were
identified included Factor H risk polymorphisms H402
(c.1204C, p.His402) in 4 patients and V62 (c.184G, p.Val62)
in 8 patients. One patient carried the C3 risk allele G102, L314
(c.304G, p.Gly102; c.941T, p.Leu314).
Laser dissection and mass spectrometry
We performed laser dissection and mass spectrometry to
determine the glomerular proteomic profile in eight cases
(Figure 2). All patients showed accumulation of AP and TCC
proteins. The deposition of C3 and C9 was extensive in all
cases, with an average of 51.3 and 13.6 spectra, respectively.
C5, C6, C7, and C8 were also present in all cases, with an
average of 8.5, 3.5, 4.8, and 9.3 spectra, respectively. The
‘spectra’ value indicates the total number of mass spectra
collected on the mass spectrometry that matched the protein
in question utilizing the proteomics software. Complement-
regulating proteins vitronectin, clusterin, and apolipoprotein
E were present in abundance. Vitronectin and clusterin are
fluid-phase regulators of TCC. CFHR-1 was present in all
cases with an average of 15.3 spectra, and CFHR-5 was
present in seven of eight cases with an average of 6 spectra.
There was little or no significant accumulation of
complement factors of the classical complement pathway,
such as C1, C2, or C4. In addition, there was little or no Ig
present. The minor spectra of various Ig, kappa, and lambda
light chain noted in a few cases likely represent protein
reabsorption granules present in the podocytes of dissected
glomeruli. In aggregate, these findings are similar to those
noted in patients with DDD.8 The last lane in Figure 2 shows
the glomerular proteomic profile in a recent case of DDD for
comparison.
Treatment and follow-up
Eight of the ten patients with native renal function were
treated with ACE inhibitors and angiotensin II blockers
(renin–angiotensin system blockade), and seven received
prednisone for 4 weeks to 1 year. In addition, three patients
(patients 1, 2, and 3) were treated with mycophenolate
mofetil (Cellcept) following prednisone taper. One patient
(patient 6) received prednisone followed by cyclophospha-
mide (Cytoxan) with stabilization of kidney function. Two
patients (patients 9 and 10) were treated conservatively with
renin–angiotensin system blockade only and did not receive
steroids or other forms of immunosuppressive therapy.
Follow-up ranged from 4 months to 23 years after renal
biopsy with a mean follow-up of 26.4 months (calculated
using a maximum of 48 months in patients followed for
longer times to avoid skewing results; Figure 3). In general,
the patients did well with no significant decline in renal
function, both in the short and long term. The mean serum T
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creatinine (except patient 5) on presentation was 1.5mg/dl
while the mean serum creatinine on follow-up decreased to
1.22mg/dl. Patient 5 presented with a serum creatinine of
3.1mg/dl and was on dialysis within 3 months of presenta-
tion. In one case (patient 8), kidney biopsy done at the age of
8 years was interpreted as MPGN type I at the time. On
review of the biopsy, the findings fulfilled all the criteria of
C3GN. A repeat kidney biopsy done 17 years later continued
to show C3GN. In this case, follow-up is available for 23 years
after the first biopsy and 6 years after the second biopsy.
Both patients with recurrent C3GN showed evidence of
recurrent disease within 1 to 1.5 years. Review of their native
kidney biopsies revealed MPGN with bright C3 and no Ig or
light-chain staining on IF, and mesangial and subendothelial
deposits on EM, fulfilling the criteria for C3GN. The native
disease was present for greater than 10 years in both patients.
The first patient received a living donor kidney transplant,
and was treated with prednisone, tacrolimus, and mycophe-
nolate mofetil. Within 1 year, the patient developed recurrent
C3GN and skin (purpuric) vasculitis. For the past 5 years, he
has been maintained on plasmapheresis during which time
his serum creatinine has risen from a baseline of 1.7 to
2.9mg/dl. The second patient received a living-related
one-haplotype match kidney transplant. The patient is on
a
c f
d
e
g
b
Figure 2 | Laser microdissection and mass spectrometry analysis of glomerular proteins in eight patients of C3 glomerulonephritis
(C3GN) and one patient of dense deposit disease (DDD). (a) Glomeruli marked before dissection in patient 5, and (b) empty space
following microdissection. (c) Representative scaffold readout of proteins of interest for eight patients of C3GN and one patient of DDD (last
column). The proteomic data show extensive accumulation of proteins of alternative pathway including C3, C9, C8, C5, C7, and C6 in order
of abundance, with 495% probability. CFHR-1, CFHR-5, vitronectin, apolipoprotein E, and clusterin are also present in relative abundance,
with 495% probability. Yellow stars indicate proteins of interest, while red stars indicate protein ambiguity when two proteins share
conserved regions. (d, e) Sequence coverage for C3 and C9 in all patients showing the number of peptides, number of unique peptides,
number of spectra, and percentage of coverage of peptide sequence for C3 (d) and C9 (e). (f) Analysis of C3 in one sample showing 21
unique peptides, 26 unique spectra, and 77 total spectra, all of which result in 16% peptide coverage with 100% probability for C3.
(g) Analysis of C9 in one sample showing 9 unique peptides, 10 unique spectra, and 22 total spectra, all of which result in 21% peptide
coverage with 100% probability for C9. The yellow highlighted areas in (f, g) shows the actual peptides detected by the mass spectrometry,
and the green highlight shows oxidized or methylated amino acids.
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prednisone, tacrolimus, and mycophenolate mofetil. The serum
creatinine has gradually increased from 1.6 to 2.1mg/dl
during 17 months of follow-up.
DISCUSSION
In this study, we have described the clinical features, kidney
biopsy findings, complement abnormalities, glomerular
protein profile, treatment, and follow-up in 12 patients with
C3GN. We found that C3GN occurred at all ages, did not
have a sex predilection, and presented with a nephritic–
nephrotic picture. Most patients had hypertension, proteinuria,
and hematuria.
Kidney biopsy showed a predominantly MPGN pattern of
injury, although mesangial proliferative, diffuse proliferative
(exudative), and crescentic glomerulonephritis were also
present, a finding consistent with other recent studies on AP-
mediated glomerulonephritis.2,3,9,10 In addition, although
not included in our series, we have seen cases of AP-mediated
glomerulonephritis that showed only mesangial expansion
with minimal hypercellularity. It is pertinent to note that in
the patients in our series, the initial diagnosis was MPGN
type I in four, MPGN type III in one, and post-infectious
glomerulonephritis in four, but in all cases review of the
biopsy clearly showed C3GN. The absence of significant Ig,
including kappa and lambda light chains on IF, should
exclude the diagnoses immune-complex MPGN types I and
III, while the misdiagnosis of post-infectious glomerulone-
phritis was likely due to the presence of subepithelial deposits.
From the pathology standpoint, the finding of bright
mesangial and capillary wall C3 in the absence of significant
Ig should prompt an evaluation of AP. Low C3 and normal
C4 serum levels also point toward AP dysfunction. By history,
there was no antecedent infection to justify a diagnosis
of post-infectious glomerulonephritis, with concurrent
infections often exacerbating clinical symptoms like hema-
turia. There did not appear to be a disease-triggering event in
these patients, and in none was evidence of persistent
infection. Evaluation for an autoimmune disease was also
negative. Monoclonal gammopathy was present in two
patients and has been described in the setting of dysregula-
tion of the AP.11
Three patients had multiple kidney biopsies, and in this
group it is pertinent that there was no observed progression
of glomerulosclerosis and tubulointerstitial scarring, even
though the glomeruli continue to show proliferative features.
These histological findings are consistent with the stable
kidney function and indeed long-term follow-up in these
patients has shown stabilization of the renal function. These
data suggest that C3GN may be less aggressive than DDD,
which progresses to end-stage renal failure in B25% of
patients after 5 years and B50% of patients after 10
years.4,12,13
Complement evaluation in all patients showed findings
consistent with AP dysfunction.2,5,14 Based on our studies, we
find that serum complement levels and an assay of AP
function (alternate pathway function assay, APFA) serve as
good screening tests to assess AP dysfunction. We found that
C3 was low and C4 was normal in 11 of 12 patients, and that
APFA was abnormal in 7 of 8 tested patients. The most
common AP abnormality was the presence of C3Nef, an
autoantibody directed against C3 convertase. By stabilizing
C3 convertase and preventing its factor H-mediated degrada-
tion, C3Nefs cause a dysregulation of AP control.4 Their
detection in 50% of C3GN patients in this series is lower than
their prevalence of B80% in DDD, where they have been
strongly implicated in disease pathogenesis.15
Another common abnormality, identified in 10 of 11
patients, was the presence of specific polymorphisms in
several complement genes. Although the small sample size
precludes definitively implicating these variants in C3GN,
they have been causally associated with DDD and age-related
macular degeneration.16–19 These polymorphisms lead to
increased baseline AP activity even in normal controls, and
studies comparing the H402 and Y402 variants of Factor H
have shown that the former is associated with poorer AP
control secondary to decreased binding to both endothelial
cells and lipid peroxidation products like malondialdehyde,
which accumulates in many pathophysiological pro-
cesses.17,18,20,21 Larger studies are required to definitely
implicate these polymorphisms in C3GN. In addition to
these specific polymorphisms, we identified a reported
disease-causing variant in CFI in one patient and novel
variants in CFH and CFHR5 in two other patients.2
There are little data on recurrent C3GN, with recurrent C3
glomerulopathy being reported in only one patient with
CFHR5 glomerulopathy.22 In the two patients we present,
both had low serum C3 and abnormal APFAs, consistent with
ongoing AP dysregulation. In one patient, C3Nefs were
identified and while the genetic analysis found risk alleles
for AP dysregulation, there was nothing unique to either
transplant recipient to suggest that their disease might be
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Figure 3 | Serum creatinine at presentation and follow-up (in
months) of all patients. Patient 5 was on dialysis soon after
presentation. Patient 8 follow-up is for 23 years, with stable kidney
function. Pt, patient.
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more aggressive. Recurrent C3GN was noted within 18
months of the transplant, a surprising outcome given the fact
that C3GN was present in both patients for more than 10
years before development of end-stage kidney disease. This
phenomenon of early recurrence with rapid loss of allograft
function compared with slow progression of disease in the
native kidney occurs with many renal diseases including
membranous nephropathy, MPGN, and focal segmental
glomerulosclerosis.7 This outcome may reflect advanced
disease at the time of transplantation and/or intrarenal
hypertension and hyperfiltration in the solitary kidney
resulting in deposition of the complement factors in the
allograft in the face of persistent disease.
The LDMS findings revealed a pattern of glomerular
complement and regulatory proteins remarkable for its
similarity to DDD.8 The two most abundant complement
proteins were C3 and C9, but there were also significant
amounts of C5, C6, C7, and C8, in aggregate consistent with
fluid-phase dysregulation of C3 and C5 convertases resulting
in accumulation of AP and TCC complement factors in the
mesangium and capillary wall with ensuing glomerular
inflammation. Both CFHR1 and CFHR5 were also present
in abundance. These findings are in stark contrast to
immune-complex-mediated MPGN, which show large spec-
tra of Ig in all cases, although the type of Ig (IgG, IgA, IgM, Ig
kappa light chains, Ig lambda light chains, and Ig heavy
chains) may vary depending on the etiology of immune-
complex-mediated MPGN. In addition, C3 and C4 are
abundant complement factors in immune-complex-mediated
MPGN while TCC complement factors and complement
regulatory proteins such as vitronectin and apolipoprotein E
are rarely present.8
As C3GN is a recently described entity, it is difficult to
make treatment recommendations. Early reports on the
treatment of ‘idiopathic’ MPGN cannot be applied to our
patients as those studies were performed in an era when the
use of renin–angiotensin system blockade was rare or non-
existent, and at a time where investigators were unaware that
complement abnormalities lead to MPGN. The majority of
early studies on treatment also included patients with all
types of MPGN.23 While some of the patients in this study
were treated with corticosteroids or other immunosuppres-
sive agents, in the absence of a properly conducted study it is
difficult to acertain their benefit. It is perhaps relevant that a
few patients who were not treated with immunosuppressive
therapy also did relatively well over time. Our impression
that C3GN is less aggressive than DDD suggests that detailed
comparisons between these two AP-mediated renal diseases
are warranted to define their commonalities and differences.
To summarize, we have presented the most comprehensive
description to date of the clinical features, pathological
findings, complement abnormalities, glomerular proteomic
profile, treatment, and follow-up in C3GN and recurrent
C3GN. Our data show that C3GN: (1) occurs at all ages
with no sex predilection; (2) presents with hematuria and
proteinuria; (3) shows a predominantly MPGN pattern on
injury on kidney biopsy; (4) is associated with fairly stable
kidney function both in the short and long term; (5) occurs
as a result of AP dysregulation that leads to glomerular
accumulation of AP and TCC proteins; and (6) results from
diverse abnormalities of the AP.
MATERIALS AND METHODS
Renal biopsies from 12 Mayo Clinic patients were evaluated. In all
cases, routine work up including LM, IF, and EM was performed.
Clinical information was obtained from the charts. Although three
patients have been previously described, longer follow-up and
detailed evaluation are now available.3 Evaluation of the AP was
performed as previously described.3 The Institutional Review Boards
at the Mayo Clinic and University of Iowa approved the study.
C3 nephritic factors
The presence of C3Nefs was analyzed by enzyme-linked immuno-
sorbent assay. Purified human C3b (Complement Technology, Tyler,
TX) was coated on a 96-well microtiter plate (pretreated with 0.2%
glutaraldehyde) overnight in 4 1C at a concentration of 10 mg/ml.
After washing three times with  1 phosphate-buffered saline
(PBS), free reactive sites were blocked with 1% bovine serum
albumin in  1 PBS for 1 h at 37 1C. To form C3 convertase, com-
plement factor B (5mg/ml) and complement factor D (0.25mg/ml)
in GVB buffer supplemented with 2mmol/l NiCl2 were added to
the washed wells followed by a 30-min incubation at 37 1C
(a non-convertase well was also included for each sample by omitting
this step). Patient serum (1:100 dilution) was added for a 25-min
incubation at 37 1C. Plates were washed with PBST ( 1 PBS with
0.5% Triton-X) and incubated for 30min at room temperature
with horseradish peroxidase-labeled goat anti-human IgG antibody
specific for the g chain. Enzymatic activity was measured using TMB
(3, 30, 5, 50-tetramethylbenzidine) and the optical density (OD) was
read at l450. An OD of þ 2 s.d. above normal based on 50 healthy
controls was considered positive.
APFA
AP complement activity was evaluated using the Wieslab comple-
ment AP assay kit (Wieslab AB, Lund, Sweden). The method
combines principles of the hemolytic assay for complement
activation with the use of labeled antibodies specific for neoantigen
produced as a result of complement activation. The amount of
neoantigen generated is proportional to the functional activity of the
AP. In brief, patient serum was diluted in diluents containing
specific blockers to ensure only AP activity. Activation was initiated
during incubation of diluted patient serum in microtiter wells
coated with specific activators of AP. The wells were washed and
C5b-9 (membrane attack complex) was detected with a specific
phosphatase-labeled antibody to the neoantigen expressed during
membrane attack complex formation. After further washing, specific
antibodies were detected by incubation with an alkaline phosphatase
substrate solution. The amount of AP activation was correlated with
color intensity and was measured as absorbance (OD). The value
reported was expressed as a percentage of normal control samples.
Control values were based on 50 normal sera samples with a normal
reference range of 65–130%.
Hemolytic assay
The sheep erythrocyte lysis assay measures complement-mediated
lysis of sheep erythrocytes secondary to AP activation. Sheep
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erythrocytes generally act as non-activators of complement-
mediated lysis in human serum. A small number of C3b molecules
spontaneously generated through AP tick-over are deposited on the
surface of sheep erythrocytes. In normal human serum, factor H
binds to C3b molecules through its N-terminal domains and to
sheep erythrocytes through its C-terminal domains. These interac-
tions result in efficient protection of sheep erythrocytes against
complement and no lysis is observed. The test was performed under
conditions specific to activation of the AP. In brief, 20 ml of patient
serum was diluted in 30 ml of GVB/Mg2þ /EGTA buffer (AP
activation possible). A duplicate dilution was prepared in GVB/
EDTA as a blank (AP activation not possible). A volume of 50 ml of
sheep erythrocytes (1 108 cells/ml in GVB/Mg2þ /EGTA buffer)
were added to the mixture and incubated at 37 1C for 30min, after
which the reaction was stopped by adding 150 ml of ice-cold GVB/
EDTA buffer, and the sample was centrifuged. A415 was measured
and the amount of lysis was calculated by subtracting A415 of the
corresponding blank and dividing by A415 associated with total lysis
(50ml of sheep erythrocytes and 200ml of water). Reference ranges
were: normal (o3%); 1þ (3–20%); 2þ (20–40%); 3þ (40–60%);
4þ (60–80%); and 5þ (80–100%, complete hemolysis).
FHAAs
The presence of FHAA was analyzed by enzyme-linked immuno-
sorbent assay. Purified human FH (Complement Technology) was
coated on a 96-well microtiter plate overnight in 4 1C at a
concentration of 5 mg/ml. After washing three times with  1 PBST
( 1PBS containing 0.5% Triton-X), free reactive sites were blocked
with 1% bovine serum albumin in  1 PBST for 1 h at room
temperature. Patient serum (1:50 dilution) was added for 1 h
incubation at room temperature. Plates were then washed and
incubated for 1 h at room temperature with a horseradish
peroxidase-labeled goat anti-human IgG antibody specific for the
g chain. After a final washing, enzymatic activity was measured
using TMB and the OD was read at l450. An OD of þ 2 s.d. above
normal based on 50 healthy controls was considered positive
(normal reference range: o300 units).
Mutational analysis
Coding regions and intron–exon boundary junctions of CFH
(MIM134370; NM_000186), CFHR5 (MIM608593; NM_030787.3),
CFI (MIM217030; NM_000204.3), CD46 (MIM120920; NM_
002389.3), CFB (MIM138470; NM_001710.5), C3 (MIM120700;
NM_000064.2), and THBD (MIM188040; NM_000361.2) were
amplified and screened for mutations and polymorphisms using
bidirectional sequencing. Polymerase chain reaction amplification of
genomic DNA was completed using 20ng genomic DNA, 2 NH4
buffer, 3mmol/l MgCl2, 400mM each dNTP, 50U/ml Taq polymerase,
and 10% DMSO. Reaction conditions consisted of initial denatura-
tion at 95 1C for 5min, 35 cycles of denaturation at 95 1C for 30 s,
annealing at 60 1C for 30 s, and extension at 72 1C for 30 s. These steps
were followed by a final extension at 72 1C for 10min.
Specimen preparation, laser microdissection, and mass
spectrometry proteomic analysis
The methods have been published previously.8,24 Briefly, for each
case, slides were made using 10 mm-thick sections of formalin-fixed
paraffin-embedded tissues stained with hematoxylin and eosin.
Laser microdissection was performed by selecting two glomeruli per
slide and studying two slides per case. The laser microdissection
material was collected in 0.5ml micro-centrifuge tube caps
containing 35 ml Tris/EDTA/0.002% Zwittergent buffer. Microdis-
sected fragments were digested into tryptic peptides overnight and
analyzed by liquid chromatography electrospray tandem mass
spectrometry (MS). MS raw data files were queried using three
different algorithms (Sequest, Mascot and X!Tandem), the results
were combined and assigned peptide and protein probability scores
in Scaffold (Proteome Software, Portland, OR). For each case, a list
of proteins based on peptides identified by MS was generated.
Peptide identifications were accepted if they could be established at
490% probability as specified by the Peptide Prophet algo-
rithm.24–26 Protein identificationso90% confidence level and those
with single-peptide identification were not considered. The ‘spectra’
value indicates the total number of mass spectra collected on the MS
and matched to the protein utilizing the proteomics software. A
higher number of mass spectra is indicative of greater abundance
and will typically yield greater amino-acid sequence coverage. A
higher mass spectra value also indicates a higher confidence in the
protein identification. Testing required a minimum number of four
spectra in all samples before the protein identification was deemed
clinically valid. The proteins were ranked according to abundance
based on the number of assigned spectra.
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